Sign in Remember me Reset your password Log in through HighQ Hub Haavind internal users If you need technical support, please email collaborate@haavind.no. © 2021 Thomson Reuters | Terms of Use | Help | GDPR contact

Skip to menu Haavind EN Your legal partner through change and digital development Our expertise News 26.10.2021 Replacment of IBOR-Rates What are the legal restrictions on lenders introducing alternative rates? 20.10.2021 Norway proposes to expand FDI filing obligation On 11 October 2021, the Ministry of Justice, together with the Ministry of Defense, published a consultation paper on changes to the Security Act. The proposed changes include an expansion of the filing obligation to new categories of targets, a lowering of the investment thresholds that trigger filing, and the introduction of a notification deadline and a stand-still obligation. 15.10.2021 New edition of Haavind’s Pharma Report Welcome to the Autumn 2021 edition of Haavind’s Pharma Report. Pharma Report is a retrospective, report on legal developments in Norway relevant for the pharmaceutical sector, covering topics both within regulatory affairs and intellectual property. The report has been published twice a year since 2016. 08.10.2021 Risk free interest rates What happens in Norway with NIBOR, and what are the legal restrictions on banks introducing alternative rates? More news Report The Haavind Pharma Report 2020 In the Pharma Report Summer 2020, we take a retrospective look at some of the legal developments during the first half of 2020 in the Norwegian pharmaceutical sector. Your legal partner through change and digital development Advokatfirmaet Haavind AS P.O. Box 359 Sentrum N-0101 OSLO Visiting address Bygdøy allé 2 N-0257 OSLO Telephone +4722433000 Organisation number 986 420 177 E-mail post@haavind.no Privacy and cookie policy © Haavind 2021